US20220020461A1 - Contextualized personalized insomnia therapy regimen, system, and method - Google Patents
Contextualized personalized insomnia therapy regimen, system, and method Download PDFInfo
- Publication number
- US20220020461A1 US20220020461A1 US17/363,714 US202117363714A US2022020461A1 US 20220020461 A1 US20220020461 A1 US 20220020461A1 US 202117363714 A US202117363714 A US 202117363714A US 2022020461 A1 US2022020461 A1 US 2022020461A1
- Authority
- US
- United States
- Prior art keywords
- insomnia
- therapy
- sleep
- recommendation
- severity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 title claims abstract description 283
- 206010022437 insomnia Diseases 0.000 title claims abstract description 283
- 238000002560 therapeutic procedure Methods 0.000 title claims abstract description 178
- 238000000034 method Methods 0.000 title claims abstract description 37
- 230000007613 environmental effect Effects 0.000 claims abstract description 15
- 230000007958 sleep Effects 0.000 claims description 68
- 230000036626 alertness Effects 0.000 claims description 25
- 238000011422 pharmacological therapy Methods 0.000 claims description 17
- 230000000694 effects Effects 0.000 claims description 14
- 230000006399 behavior Effects 0.000 claims description 13
- 208000024891 symptom Diseases 0.000 claims description 12
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 10
- 208000017667 Chronic Disease Diseases 0.000 claims description 5
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 5
- 229960001948 caffeine Drugs 0.000 claims description 5
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 5
- 238000012549 training Methods 0.000 claims description 5
- 208000010340 Sleep Deprivation Diseases 0.000 claims description 4
- 231100000430 skin reaction Toxicity 0.000 claims description 4
- 210000000744 eyelid Anatomy 0.000 claims description 3
- 238000010801 machine learning Methods 0.000 claims description 3
- 230000004622 sleep time Effects 0.000 claims description 3
- 238000011338 personalized therapy Methods 0.000 abstract description 6
- 230000036541 health Effects 0.000 abstract description 4
- 230000003542 behavioural effect Effects 0.000 abstract description 3
- 238000011156 evaluation Methods 0.000 description 10
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 230000003860 sleep quality Effects 0.000 description 7
- 230000009467 reduction Effects 0.000 description 6
- 238000013507 mapping Methods 0.000 description 4
- 238000000586 desensitisation Methods 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 206010052804 Drug tolerance Diseases 0.000 description 2
- 206010027590 Middle insomnia Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- 238000009108 consolidation therapy Methods 0.000 description 2
- 229960001578 eszopiclone Drugs 0.000 description 2
- GBBSUAFBMRNDJC-INIZCTEOSA-N eszopiclone Chemical compound C1CN(C)CCN1C(=O)O[C@H]1C2=NC=CN=C2C(=O)N1C1=CC=C(Cl)C=N1 GBBSUAFBMRNDJC-INIZCTEOSA-N 0.000 description 2
- 230000026781 habituation Effects 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 238000001050 pharmacotherapy Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- KBAUFVUYFNWQFM-UHFFFAOYSA-N Doxylamine succinate Chemical compound OC(=O)CCC(O)=O.C=1C=CC=NC=1C(C)(OCCN(C)C)C1=CC=CC=C1 KBAUFVUYFNWQFM-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 244000178870 Lavandula angustifolia Species 0.000 description 1
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 1
- YLXDSYKOBKBWJQ-LBPRGKRZSA-N N-[2-[(8S)-2,6,7,8-tetrahydro-1H-cyclopenta[e]benzofuran-8-yl]ethyl]propanamide Chemical compound C1=C2OCCC2=C2[C@H](CCNC(=O)CC)CCC2=C1 YLXDSYKOBKBWJQ-LBPRGKRZSA-N 0.000 description 1
- SEQDDYPDSLOBDC-UHFFFAOYSA-N Temazepam Chemical compound N=1C(O)C(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 SEQDDYPDSLOBDC-UHFFFAOYSA-N 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000009225 cognitive behavioral therapy Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
- 229960005426 doxepin Drugs 0.000 description 1
- 229960005008 doxylamine succinate Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000000938 histamine H1 antagonist Substances 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 239000001102 lavandula vera Substances 0.000 description 1
- 235000018219 lavender Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229960001150 ramelteon Drugs 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 238000011125 single therapy Methods 0.000 description 1
- 230000008667 sleep stage Effects 0.000 description 1
- JYTNQNCOQXFQPK-MRXNPFEDSA-N suvorexant Chemical compound C([C@H]1C)CN(C=2OC3=CC=C(Cl)C=C3N=2)CCN1C(=O)C1=CC(C)=CC=C1N1N=CC=N1 JYTNQNCOQXFQPK-MRXNPFEDSA-N 0.000 description 1
- 229960001198 suvorexant Drugs 0.000 description 1
- 229960003188 temazepam Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960003386 triazolam Drugs 0.000 description 1
- JOFWLTCLBGQGBO-UHFFFAOYSA-N triazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl JOFWLTCLBGQGBO-UHFFFAOYSA-N 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 229960004010 zaleplon Drugs 0.000 description 1
- HUNXMJYCHXQEGX-UHFFFAOYSA-N zaleplon Chemical compound CCN(C(C)=O)C1=CC=CC(C=2N3N=CC(=C3N=CC=2)C#N)=C1 HUNXMJYCHXQEGX-UHFFFAOYSA-N 0.000 description 1
- 229960001475 zolpidem Drugs 0.000 description 1
- ZAFYATHCZYHLPB-UHFFFAOYSA-N zolpidem Chemical compound N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1 ZAFYATHCZYHLPB-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
- G09B—EDUCATIONAL OR DEMONSTRATION APPLIANCES; APPLIANCES FOR TEACHING, OR COMMUNICATING WITH, THE BLIND, DEAF OR MUTE; MODELS; PLANETARIA; GLOBES; MAPS; DIAGRAMS
- G09B19/00—Teaching not covered by other main groups of this subclass
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
- A61B5/0205—Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
- A61B5/024—Detecting, measuring or recording pulse rate or heart rate
- A61B5/02405—Determining heart rate variability
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
- A61B5/053—Measuring electrical impedance or conductance of a portion of the body
- A61B5/0531—Measuring skin impedance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/08—Detecting, measuring or recording devices for evaluating the respiratory organs
- A61B5/0806—Detecting, measuring or recording devices for evaluating the respiratory organs by whole-body plethysmography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
- A61B5/14551—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters for measuring blood gases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/16—Devices for psychotechnics; Testing reaction times ; Devices for evaluating the psychological state
- A61B5/165—Evaluating the state of mind, e.g. depression, anxiety
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4806—Sleep evaluation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4806—Sleep evaluation
- A61B5/4815—Sleep quality
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4806—Sleep evaluation
- A61B5/4818—Sleep apnoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
- A61B5/4839—Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4842—Monitoring progression or stage of a disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/486—Bio-feedback
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7235—Details of waveform analysis
- A61B5/7264—Classification of physiological signals or data, e.g. using neural networks, statistical classifiers, expert systems or fuzzy systems
- A61B5/7267—Classification of physiological signals or data, e.g. using neural networks, statistical classifiers, expert systems or fuzzy systems involving training the classification device
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7271—Specific aspects of physiological measurement analysis
- A61B5/7275—Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/74—Details of notification to user or communication with user or patient ; user input means
- A61B5/7475—User input or interface means, e.g. keyboard, pointing device, joystick
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/0003—Accessories therefor, e.g. sensors, vibrators, negative pressure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/021—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes operated by electrical means
- A61M16/022—Control means therefor
- A61M16/024—Control means therefor including calculation means, e.g. using a processor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/021—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes operated by electrical means
- A61M16/022—Control means therefor
- A61M16/024—Control means therefor including calculation means, e.g. using a processor
- A61M16/026—Control means therefor including calculation means, e.g. using a processor specially adapted for predicting, e.g. for determining an information representative of a flow limitation during a ventilation cycle by using a root square technique or a regression analysis
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
- G06N20/00—Machine learning
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
- G06N3/00—Computing arrangements based on biological models
- G06N3/02—Neural networks
- G06N3/08—Learning methods
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
- G06N5/00—Computing arrangements using knowledge-based models
- G06N5/02—Knowledge representation; Symbolic representation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/20—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/30—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to physical therapies or activities, e.g. physiotherapy, acupressure or exercising
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/40—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/60—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to nutrition control, e.g. diets
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/70—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mental therapies, e.g. psychological therapy or autogenous training
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/63—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/67—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/50—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2560/00—Constructional details of operational features of apparatus; Accessories for medical measuring apparatus
- A61B2560/02—Operational features
- A61B2560/0242—Operational features adapted to measure environmental factors, e.g. temperature, pollution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2560/00—Constructional details of operational features of apparatus; Accessories for medical measuring apparatus
- A61B2560/02—Operational features
- A61B2560/0242—Operational features adapted to measure environmental factors, e.g. temperature, pollution
- A61B2560/0247—Operational features adapted to measure environmental factors, e.g. temperature, pollution for compensation or correction of the measured physiological value
- A61B2560/0257—Operational features adapted to measure environmental factors, e.g. temperature, pollution for compensation or correction of the measured physiological value using atmospheric pressure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2562/00—Details of sensors; Constructional details of sensor housings or probes; Accessories for sensors
- A61B2562/02—Details of sensors specially adapted for in-vivo measurements
- A61B2562/0219—Inertial sensors, e.g. accelerometers, gyroscopes, tilt switches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/103—Detecting, measuring or recording devices for testing the shape, pattern, colour, size or movement of the body or parts thereof, for diagnostic purposes
- A61B5/11—Measuring movement of the entire body or parts thereof, e.g. head or hand tremor, mobility of a limb
- A61B5/1118—Determining activity level
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3303—Using a biosensor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/35—Communication
- A61M2205/3576—Communication with non implanted data transmission devices, e.g. using external transmitter or receiver
- A61M2205/3584—Communication with non implanted data transmission devices, e.g. using external transmitter or receiver using modem, internet or bluetooth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/50—General characteristics of the apparatus with microprocessors or computers
- A61M2205/502—User interfaces, e.g. screens or keyboards
Definitions
- the present invention pertains to a system and method for providing a recommendation of an insomnia therapy and, in particular, to an apparatus and method to leverage various metrics including personal health profile, 24/7 biometrics, behavioral information, and environmental stressors to predict insomnia severity, to build a personalized severity and type insomnia therapy map ranked by historic therapy efficacy, to provide a contextualized personalized therapy recommendation, and to optimize the insomnia therapy.
- Insomnia interventions include Cognitive Behavioral Therapy for Insomnia (CBTI) and pharmacologic therapy.
- CBTI is typically regarded as the gold standard for insomnia as it is typically considered curative.
- CBTI often requires in-person therapy sessions by a trained clinician.
- digital CBTI programs have been developed in order to increase the availability of this curative therapy.
- CBTI While effective, it typically requires the user to go through a series of modules, including sleep consolidation therapy (or sleep restriction therapy), stimulus control instructions, sleep hygiene education, relaxation techniques, and cognitive techniques. While effective, CBTI requires commitment and behavior change in order for a patient to see successful outcomes, where sleep consolidation therapy, in particular, requires an extended period of time where the user may build a significant amount of sleep debt and may thus have difficulty maintaining daytime alertness. Thus, CBTI, while effective, often suffers from poor adherence, especially with digital versions.
- insomnia either OTC (e.g. sedative antihistamines) or prescription
- OTC e.g. sedative antihistamines
- prescription e.g. sedative antihistamines
- insomnia sufferers are not given daily dosing strategies, and pharmacotherapy suffers from a risk of tolerance and habituation. Improvements in the treatment of insomnia thus would be desirable.
- an object of the present invention to provide an improved system and method for providing insomnia therapy that overcome the shortcomings of conventional systems and methods for providing and assessing insomnia therapy.
- This object is achieved according to one embodiment of the present invention by providing an apparatus and method that leverage various metrics including one or more of a personal health profile, 24/7 biometrics, behavioral information, and environmental stressors to predict insomnia severity, to build a personalized severity and type insomnia therapy map ranked by historic therapy efficacy, to provide a contextualized personalized therapy recommendation, and to optimize the insomnia therapy
- the system and method of the disclosed and claimed concept advantageously meet these and other objectives.
- the overall concept of the disclosed and claimed concept includes 24/7 personal and environmental sensing/monitoring, insomnia severity estimation and type trending from insomnia symptoms, insomnia severity prediction from behaviors, biometrics, and stressors (personal and/or environmental), and therapy recommendation from personalized insomnia severity and type therapy mapping, and therapy efficacy evaluation.
- the system advantageously includes a predictive model to estimate insomnia severity through monitoring a user's personal profile (e.g. Electronic Health Record (EHR) that documents patient conditions such as chronic conditions, meds, etc.), behaviors, biometrics, and personal/environmental stressors (e.g. temperature, stressful events, stress level, activity level and intensity and timing), sleep metrics (e.g. naps and timing), sleep related behaviors (e.g. caffeine and alcohol consumption and timing) and a recommendation module to provide a personalized insomnia therapy recommendation with the maximum possible efficacy to the user.
- EHR Electronic Health Record
- biometrics e.g. temperature, stressful events, stress level, activity level and intensity and timing
- sleep metrics e.g. naps and timing
- sleep related behaviors e.g. caffeine and alcohol consumption and timing
- the core therapy for insomnia is CBTI, it also may be required to additionally prescribe a number of medications if CBTI alone doesn't improve the condition(s).
- the expression “a number of” and variations thereof shall refer broadly to any non-zero quantity, including a quantity of one.
- the prescribed medication(s) could be different.
- suvorexant and doxepin are recommended for sleep maintenance insomnia
- zaleplon, triazolam, and ramelteon are recommended for sleep onset insomnia.
- Some of the medicines are type-agnostic, such as, eszopiclone, zolpidem, and temazepam. Therefore, the proposed system advantageously considers both insomnia severity and insomnia type when building the personalized insomnia therapy map.
- the system also includes an insomnia metrics evaluation module to estimate an insomnia severity and to also trend over time an insomnia type based on various sleep metrics (e.g. Sleep Onset Latency (SOL), Wake After Sleep Onset (WASO), Sleep Efficiency (SE), number of awakenings and associated durations, Total Sleep Time (TST)) and alertness metrics (e.g. PERCLOS—PERcentage of eyelid CLOSure over the time).
- sleep metrics e.g. Sleep Onset Latency (SOL), Wake After Sleep Onset (WASO), Sleep Efficiency (SE), number of awakenings and associated durations, Total Sleep Time (TST)
- alertness metrics e.g. PERCLOS—PERcentage of eyelid CLOSure over the time.
- the system includes a therapy efficacy evaluation module to evaluate the efficacy of various insomnia therapies based on a comparison between the actual insomnia severity and the predicted insomnia severity, where the actual insomnia severity is estimated by the aforementioned insomnia metrics evaluation module.
- the improved system builds a personalized insomnia therapy map that includes insomnia severity and insomnia type versus therapy and is sorted based on the efficacy of the therapy (i.e. the top of the list has the maximum efficacy). Additionally, the system advantageously provides therapy regimen switching or cycling among available insomnia therapies in order to avoid desensitization to the interventions and potential side effects. Especially when the system recommends a less efficacious therapy, such as to avoid desensitization to a more effective therapy, it may recommend multiple prioritized interventions during a given period of attempted sleep, i.e., for a given evening, in order to maintain efficacy. As the system is continuously used by a user, this insomnia therapy map will be updated to better reflect the various insomnia therapies that have been effective for the person, i.e., the patient, so that the system and insomnia therapy map advantageously support the personalized therapy recommendations.
- an improved method of providing a recommendation of an insomnia therapy to a patient including, for each of a plurality of periods of attempted sleep by the patient, determining a predicted insomnia severity that is based at least in part upon an insomnia severity prediction model, outputting a recommendation of an insomnia therapy from among a plurality of insomnia therapies based at least in part upon the predicted insomnia severity and an insomnia therapy map of the patient, the insomnia therapy map including a corresponding efficacy for each of the plurality of insomnia therapies, determining an actual insomnia severity that is based at least in part upon a number of insomnia symptoms in the patient, determining an efficacy of the insomnia therapy based at least in part upon the predicted insomnia severity and the actual insomnia severity, and updating the insomnia therapy map to reflect the efficacy.
- an improved system structured and configured to provide a recommendation of an insomnia therapy to a patient, the general nature of which can be stated as including a processor apparatus that can be generally stated as including a processor and a storage, an input apparatus structured to provide input signals to the processor apparatus and that can be generally stated as including one or more of a sleep metrics sensing module that can be generally stated as including a photoplethysmogram (PPG), an alertness sensing module, an activity metrics sensing module that can be generally stated as including at least one of a step counter and a Global Positioning System (GPS) sensor, a personal and environmental stressor sensing module that can be generally stated as including at least one of a Galvanic Skin Response (GSR) sensor and a room temperature sensor, a related behaviors sensing module, and a personal profile, an output apparatus structured to receive output signals from the processor apparatus and to generate outputs, the storage having stored therein a number of routines which, when executed on the processor, cause the system to perform operations that can be generally stated
- a processor apparatus that can be generally
- FIG. 1 is a depiction of an improved system in accordance with an aspect of the disclosed and claimed concept
- FIG. 2 is a depiction of a training phase for building an insomnia severity prediction model of the system of FIG. 1 ;
- FIG. 3 is a depiction of a training phase for building an insomnia therapy map of the system of FIG. 1 ;
- FIG. 4 is a depiction of the system of FIG. 1 in a deployment phase
- FIG. 5 is a further depiction of the system of FIG. 4 ;
- FIG. 6 is a flow chart depicting certain aspects of an improved method in accordance with the disclosed and claimed concept.
- the word “unitary” means a component is created as a single piece or unit. That is, a component that includes pieces that are created separately and then coupled together as a unit is not a “unitary” component or body.
- the statement that two or more parts or components “engage” one another shall mean that the parts exert a force against one another either directly or through one or more intermediate parts or components.
- the term “number” shall mean one or an integer greater than one (i.e., a plurality).
- the disclosed and claimed system 4 and method advantageously collects personal profile data (e.g. EHR (chronic condition(s), medication(s)) and monitors various metrics including but not limited to sleep metrics (e.g. WASO, SOL, SE, TST, number of awakenings, sleep stages), activity metrics (e.g. step count, duration, distance, intensity, timing), alertness metrics (e.g. PERCLOS, nap frequency, nap duration), stressors (e.g. Heart Rate (HR), blood pressure, skin conductance, environment temperature), behaviors (e.g. sleep hygiene, caffeine intake frequency and timing), etc.
- sleep metrics e.g. WASO, SOL, SE, TST, number of awakenings, sleep stages
- activity metrics e.g. step count, duration, distance, intensity, timing
- alertness metrics e.g. PERCLOS, nap frequency, nap duration
- stressors e.g. Heart Rate (HR), blood pressure, skin conductance, environment temperature
- behaviors e.g. sleep hygiene, caffeine intake frequency and timing
- a patient's insomnia severity is defined by a set of predetermined levels.
- the predetermined levels are four in quantity (e.g. none, mild, moderate, and severe) based on validated Insomnia Severity Index (ISI).
- the disclosed and claimed concept advantageously uses multiple sensors, such as may include one or more of a photoplethysmogram (PPG), a step counter, a Global Positioning System (GPS) sensor, a HR sensor, a Galvanic Skin Response (GSR) sensor, a room temperature sensor) to obtain a number of objective insomnia-related physiological measures, such as, SOL, WASO, SE, TST, activity timing, duration, and intensity, and alertness, and further develops a formula to integrate all the various metrics into an insomnia severity score (e.g. maximum is 100) and map to a predefined insomnia severity level.
- the formula can be any type of polynomial or other formula that can combine the various metrics and weight them according to various criteria, etc. In some embodiments, this mapping can be shown as in the following Table 1:
- This method can be used for evaluating the actual insomnia severity level while an insomnia therapy (or no therapy) is applied to an individual patient.
- this module advantageously trends an insomnia type over a predefined moving time window (e.g. weekly) to inform the therapy recommendation.
- the present invention captures the indications/data that are relevant insomnia severity.
- These indications/data include one or more of sleep metrics (last night), sleep debt, stress level, caffeine intake amount and timing, late and hard exercises, hot or cold room temperature, etc. and are collected through a sleep metrics sensing module 74 , a related behaviors sensing module 90 , an activity metrics sensing module 78 , a personal stressor sensing module 83 , an environmental stressor sensing module 84 , and a personal profile 92 (e.g. chronic conditions and other conditions).
- the system 4 collects insomnia metrics such as sleep metrics (tonight) via a sleep metrics sensing module 72 and alertness metrics (tomorrow) via an alertness sensing module 76 to evaluate the insomnia severity via an insomnia metrics evaluation module 40 that can be said to include the sleep metrics sensing module 72 and the alertness sensing module 76 .
- the disclosed and claimed concept advantageously builds a machine learning model in a training phase as illustrated in FIG. 2 .
- this model is used as an insomnia severity prediction model 8 to predict an actual insomnia severity level (e.g. tonight) based on one or more of the relevant behaviors, biometrics, and personal/environmental stressors (e.g. past 24 hours), and projected bedtime, by way of example.
- the disclosed and claimed concept advantageously creates a personalized insomnia therapy map that tracks insomnia severity and insomnia type based on the history of therapy efficacy in the individual patient.
- the disclosed and claimed concept advantageously begins with a default insomnia therapy map that is not yet personalized but that is instead based initially upon population data such as can be derived from clinical guidelines, clinical study results, review articles, etc.
- a default insomnia therapy map that is not yet personalized but that is instead based initially upon population data such as can be derived from clinical guidelines, clinical study results, review articles, etc.
- the proposed system tracks the specific therapy the actual insomnia severity, and the insomnia type and also evaluates the resultant therapy efficacy so that a personalized insomnia severity and type therapy map can be built based on history of the personalized therapy efficacy.
- CBTI is the core therapy for insomnia and it contains multiple aspects such as, sleep hygiene education, sleep restriction therapy, etc.
- CBTI therapy contains many possible methods.
- CBTI alone might not be enough, and additional pharmacological therapy might be required for an individual.
- some medications are specific to certain type of insomnia.
- the disclosed and claimed concept thus advantageously also trends the insomnia type of an individual patient over the predefined period of time to inform the proper choice of the medication, if needed.
- the disclosed and claimed concept advantageously also includes the insomnia type along with the insomnia severity in the insomnia therapy map.
- the disclosed and claimed concept advantageously saves up to a predefined quantity of therapies (up to three, by way of example) for each combination of insomnia severity level and insomnia type so that a plurality of personalized alternative and optional insomnia therapies can be recommended as well.
- the exemplary insomnia therapy map illustrated in Table 2 below is organized as a ranked list for each severity level based on the statistics of efficacy history of an individual.
- each therapy ID in Table 2 can be one or more specific therapy methods.
- Therapy ID 1 represents CBTI 1 (e.g. “choose a relaxing activity for half an hour before bedtime”) as illustrated in Table 3 below.
- Therapy ID 7 represents a combination of CBTI 1 and Med N (e.g. eszopiclone).
- this table becomes enhanced and personalized.
- the disclosed and claimed concept advantageously creates a therapy efficacy evaluation module or method to evaluate therapy efficacy.
- the disclosed and claimed concept advantageously evaluates the therapy efficacy through the following processes.
- Sleep quality score The disclosed and claimed concept advantageously determines a sleep quality score by using various sleep metrics (e.g., using one or more of SE, WASO, number of awakenings, SOL, deep sleep percentage, TST, etc.).
- the disclosed and claimed concept advantageously monitors the sleep metrics of a patient during the night while a specific therapy is in use.
- the maximum sleep quality score representing the best sleep quality is defined as 100.
- Alertness score The disclosed and claimed concept advantageously determines a next-day alertness score by using various metrics (e.g. PERCLOS, number of naps, and duration of naps). The disclosed and claimed concept advantageously monitors these metrics during the day after applying a therapy and evaluates the alertness score.
- the maximum alertness score corresponding to the maximum alertness is defined as 100.
- the disclosed and claimed concept advantageously compares the predicted insomnia severity (i.e. before going to the bed) from the insomnia severity prediction model 8 with the actual insomnia severity informed by the aforementioned sleep quality score and alertness score via an insomnia metrics evaluation module 24 (i.e. measured during the night while a specific therapy is in use) to estimate the reduction score.
- the insomnia metrics evaluation module combines the results from the sleep quality score and the alertness score into a composite score (i.e. insomnia severity score) that corresponds to a predefined severity level.
- the reduction score is determined via a percentage reduction by using a ratio (e.g. actual insomnia severity score/predicted insomnia severity score).
- the reduction score is evaluated by the difference between the predicted insomnia severity score and the actual severity score.
- the maximum reduction score is defined as 100 which represents the maximum efficacy.
- the disclosed and claimed concept advantageously evaluates the therapy efficacy for each therapy used by a patient and saves the therapy efficacy along with the insomnia severity and the insomnia type and the specific therapy in the personalized insomnia therapy map so that the insomnia therapy map reflect the ongoing therapy efficacy in the patient of the various insomnia therapies that have been employed.
- a building phase for building the insomnia therapy map is illustrated in FIG. 3 . This insomnia therapy map evolves as the patient continues to use the system.
- the system 4 advantageously creates a default therapy list (e.g. single therapy or combined therapy) with a number of insomnia severities and a number of insomnia types along with a number of potential therapy efficacies that may be based upon population data or otherwise.
- the disclosed and claimed system advantageously uses this default list to initially provide an insomnia therapy recommendation.
- the personalized insomnia therapy map 44 that lists insomnia severity and insomnia type and that is ranked by corresponding therapy efficacy is built, and the system 4 uses the insomnia therapy map 44 to provides a personalized recommendation to achieve optimized therapy efficacy and to improve sleep quality of the patient as illustrated in FIG. 4 .
- the system 4 includes a therapy recommendation module 48 that prioritizes therapy swapping in order to avoid desensitization, habituation, or potential side effects from chronic usage of a given therapy regimen.
- a therapy recommendation module 48 that prioritizes therapy swapping in order to avoid desensitization, habituation, or potential side effects from chronic usage of a given therapy regimen.
- prescription hypnotics are not recommended for any more than, for instance, seven days per month.
- diphenhydramine and doxylamine succinate OTC sedating antihistamines
- the tolerance effect for each sleep intervention is tracked independently and, when a suspected tolerance is detected as having begun to be built, as detected as a reduced efficacy of the therapeutic intervention, as tracked and trended by a therapy efficacy evaluation module 52 of the system, the intervention is not recommended for a specific “abstinence period” (e.g. two weeks).
- “no intervention required” is suggested for nights when predicted insomnia severity is low.
- typical sleep hygiene advice can be given on nights when predicted insomnia severity is low (e.g. messaging such as, “You've had a great day today and it'll soon be time to be ready for a great night. Remember to take time to wind down before bed tonight. A nice, calming activity before bed helps prepare the mind and body for rest.”).
- a placebo treatment may be recommended on nights with low to moderate insomnia severity (e.g. lavender, etc.).
- Apparatus 4 can be employed in performing an improved method 100 that is likewise in accordance with the disclosed and claimed concept and at least a portion of which is depicted in a schematic fashion in FIG. 6 .
- Apparatus 4 can be characterized as including a processor apparatus 56 that can be said to include a processor 60 and a storage 64 that are connected with one another.
- Storage 64 is in the form of a non-transitory storage medium that has stored therein a number of routines 68 that are likewise in the form of a non-transitory storage medium and that include instructions which, when executed on processor 60 , cause apparatus 4 to perform certain operations such as are mentioned elsewhere herein.
- system 4 includes the sleep metrics sensing module 72 comprising a photoplethysmogram (PPG) 74 , the alertness sensing module 76 , the activity metrics sensing module 78 comprising at least one of a step counter 80 and a Global Positioning System (GPS) sensor 82 , the personal stressor sensing module 83 comprising a Galvanic Skin Response (GSR) sensor 86 , the environmental stressor sensing module 84 comprising a room temperature sensor 88 , the related behaviors sensing module 90 , and the personal profile 92 of the patient.
- GSR Galvanic Skin Response
- System 4 further includes an output apparatus 96 that receives output signals from processor 60 and that provides outputs that are detectable by the patient, such as audible outputs, visual outputs, and the like without limitation.
- the method 100 For each of a plurality of periods of attempted sleep by the patient, the method 100 performs the operations depicted generally in FIG. 6 . For instance, the method 100 includes determining, as at 105 , a predicted insomnia severity based upon inputs from the insomnia severity prediction model 8 . The method 100 also includes outputting, as at 110 , a recommendation of an insomnia therapy based upon the predicted insomnia severity and input from the insomnia therapy map 44 . The method 100 also includes determining, as at 115 , an actual insomnia severity that is based upon a number of insomnia symptoms in the patient. The various insomnia symptoms can be obtained via input apparatus 94 .
- the method 100 further includes determining, as at 120 , an efficacy of the insomnia therapy based upon the predicted insomnia severity and the actual insomnia severity.
- the method 100 also includes, as at 125 , updating the insomnia therapy map 44 to reflect the efficacy. Such operations are repeated, as noted hereinbefore, for each of a plurality of periods of attempted sleep by the patient. Over time, therefore, the insomnia therapy map 44 is gradually personalized to the patient in order to provide improved recommendations of insomnia therapies, which is desirable for the patient. Other benefits will be apparent.
- any reference signs placed between parentheses shall not be construed as limiting the claim.
- the word “comprising” or “including” does not exclude the presence of elements or steps other than those listed in a claim.
- several of these means may be embodied by one and the same item of hardware.
- the word “a” or “an” preceding an element does not exclude the presence of a plurality of such elements.
- any device claim enumerating several means several of these means may be embodied by one and the same item of hardware.
- the mere fact that certain elements are recited in mutually different dependent claims does not indicate that these elements cannot be used in combination.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Epidemiology (AREA)
- Primary Health Care (AREA)
- Data Mining & Analysis (AREA)
- Artificial Intelligence (AREA)
- Theoretical Computer Science (AREA)
- Psychiatry (AREA)
- Physiology (AREA)
- Databases & Information Systems (AREA)
- Mathematical Physics (AREA)
- Evolutionary Computation (AREA)
- Software Systems (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Pulmonology (AREA)
- General Physics & Mathematics (AREA)
- Business, Economics & Management (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Computing Systems (AREA)
- Signal Processing (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Anesthesiology (AREA)
Abstract
Description
- This application claims the benefit of U.S. Provisional Application No. 63/054,197, filed on 20 Jul. 2020. This application is hereby incorporated by reference herein.
- The present invention pertains to a system and method for providing a recommendation of an insomnia therapy and, in particular, to an apparatus and method to leverage various metrics including personal health profile, 24/7 biometrics, behavioral information, and environmental stressors to predict insomnia severity, to build a personalized severity and type insomnia therapy map ranked by historic therapy efficacy, to provide a contextualized personalized therapy recommendation, and to optimize the insomnia therapy.
- Insomnia interventions include Cognitive Behavioral Therapy for Insomnia (CBTI) and pharmacologic therapy. CBTI is typically regarded as the gold standard for insomnia as it is typically considered curative. However, CBTI often requires in-person therapy sessions by a trained clinician. Recently, digital CBTI programs have been developed in order to increase the availability of this curative therapy.
- However, while CBTI is effective, it typically requires the user to go through a series of modules, including sleep consolidation therapy (or sleep restriction therapy), stimulus control instructions, sleep hygiene education, relaxation techniques, and cognitive techniques. While effective, CBTI requires commitment and behavior change in order for a patient to see successful outcomes, where sleep consolidation therapy, in particular, requires an extended period of time where the user may build a significant amount of sleep debt and may thus have difficulty maintaining daytime alertness. Thus, CBTI, while effective, often suffers from poor adherence, especially with digital versions.
- Low adherence to CBTI, especially digital CBTI programs, is an issue that limits effectiveness of insomnia treatment. Specifically, it has been difficult to determine which specific therapy or combination of therapies works for an individual. These difficulties are a significant cause of prolonged unimproved insomnia conditions, associated metabolic conditions, and cognitive deficiencies.
- Thus, pharmacotherapy (either OTC (e.g. sedative antihistamines) or prescription) remains the most common intervention for insomnia. However, insomnia sufferers are not given daily dosing strategies, and pharmacotherapy suffers from a risk of tolerance and habituation. Improvements in the treatment of insomnia thus would be desirable.
- Accordingly, it is an object of the present invention to provide an improved system and method for providing insomnia therapy that overcome the shortcomings of conventional systems and methods for providing and assessing insomnia therapy. This object is achieved according to one embodiment of the present invention by providing an apparatus and method that leverage various metrics including one or more of a personal health profile, 24/7 biometrics, behavioral information, and environmental stressors to predict insomnia severity, to build a personalized severity and type insomnia therapy map ranked by historic therapy efficacy, to provide a contextualized personalized therapy recommendation, and to optimize the insomnia therapy
- Without knowing what insomnia therapy works for a person and when to apply it on a daily basis, an insomnia therapy cannot achieve its expected efficacy. The system and method of the disclosed and claimed concept advantageously meet these and other objectives. The overall concept of the disclosed and claimed concept includes 24/7 personal and environmental sensing/monitoring, insomnia severity estimation and type trending from insomnia symptoms, insomnia severity prediction from behaviors, biometrics, and stressors (personal and/or environmental), and therapy recommendation from personalized insomnia severity and type therapy mapping, and therapy efficacy evaluation.
- The system advantageously includes a predictive model to estimate insomnia severity through monitoring a user's personal profile (e.g. Electronic Health Record (EHR) that documents patient conditions such as chronic conditions, meds, etc.), behaviors, biometrics, and personal/environmental stressors (e.g. temperature, stressful events, stress level, activity level and intensity and timing), sleep metrics (e.g. naps and timing), sleep related behaviors (e.g. caffeine and alcohol consumption and timing) and a recommendation module to provide a personalized insomnia therapy recommendation with the maximum possible efficacy to the user.
- Although the core therapy for insomnia is CBTI, it also may be required to additionally prescribe a number of medications if CBTI alone doesn't improve the condition(s). As employed herein, the expression “a number of” and variations thereof shall refer broadly to any non-zero quantity, including a quantity of one. For different types of insomnia (e.g. sleep onset insomnia, sleep maintenance insomnia, etc.), the prescribed medication(s) could be different. For instance, suvorexant and doxepin are recommended for sleep maintenance insomnia, whereas zaleplon, triazolam, and ramelteon are recommended for sleep onset insomnia. Some of the medicines are type-agnostic, such as, eszopiclone, zolpidem, and temazepam. Therefore, the proposed system advantageously considers both insomnia severity and insomnia type when building the personalized insomnia therapy map.
- The system also includes an insomnia metrics evaluation module to estimate an insomnia severity and to also trend over time an insomnia type based on various sleep metrics (e.g. Sleep Onset Latency (SOL), Wake After Sleep Onset (WASO), Sleep Efficiency (SE), number of awakenings and associated durations, Total Sleep Time (TST)) and alertness metrics (e.g. PERCLOS—PERcentage of eyelid CLOSure over the time).
- Furthermore, the system includes a therapy efficacy evaluation module to evaluate the efficacy of various insomnia therapies based on a comparison between the actual insomnia severity and the predicted insomnia severity, where the actual insomnia severity is estimated by the aforementioned insomnia metrics evaluation module.
- To provide a personalized therapy recommendation, the improved system builds a personalized insomnia therapy map that includes insomnia severity and insomnia type versus therapy and is sorted based on the efficacy of the therapy (i.e. the top of the list has the maximum efficacy). Additionally, the system advantageously provides therapy regimen switching or cycling among available insomnia therapies in order to avoid desensitization to the interventions and potential side effects. Especially when the system recommends a less efficacious therapy, such as to avoid desensitization to a more effective therapy, it may recommend multiple prioritized interventions during a given period of attempted sleep, i.e., for a given evening, in order to maintain efficacy. As the system is continuously used by a user, this insomnia therapy map will be updated to better reflect the various insomnia therapies that have been effective for the person, i.e., the patient, so that the system and insomnia therapy map advantageously support the personalized therapy recommendations.
- Accordingly, aspects of the disclosed and claimed concept are provided by an improved method of providing a recommendation of an insomnia therapy to a patient, the general nature of which can be stated as including, for each of a plurality of periods of attempted sleep by the patient, determining a predicted insomnia severity that is based at least in part upon an insomnia severity prediction model, outputting a recommendation of an insomnia therapy from among a plurality of insomnia therapies based at least in part upon the predicted insomnia severity and an insomnia therapy map of the patient, the insomnia therapy map including a corresponding efficacy for each of the plurality of insomnia therapies, determining an actual insomnia severity that is based at least in part upon a number of insomnia symptoms in the patient, determining an efficacy of the insomnia therapy based at least in part upon the predicted insomnia severity and the actual insomnia severity, and updating the insomnia therapy map to reflect the efficacy.
- Other aspects of the disclosed and claimed concept are provided by an improved system structured and configured to provide a recommendation of an insomnia therapy to a patient, the general nature of which can be stated as including a processor apparatus that can be generally stated as including a processor and a storage, an input apparatus structured to provide input signals to the processor apparatus and that can be generally stated as including one or more of a sleep metrics sensing module that can be generally stated as including a photoplethysmogram (PPG), an alertness sensing module, an activity metrics sensing module that can be generally stated as including at least one of a step counter and a Global Positioning System (GPS) sensor, a personal and environmental stressor sensing module that can be generally stated as including at least one of a Galvanic Skin Response (GSR) sensor and a room temperature sensor, a related behaviors sensing module, and a personal profile, an output apparatus structured to receive output signals from the processor apparatus and to generate outputs, the storage having stored therein a number of routines which, when executed on the processor, cause the system to perform operations that can be generally stated as including, for each of a plurality of periods of attempted sleep by the patient, determining a predicted insomnia severity that is based at least in part upon an insomnia severity prediction model, outputting a recommendation of an insomnia therapy from among a plurality of insomnia therapies based at least in part upon the predicted insomnia severity and an insomnia therapy map of the patient, the insomnia therapy map including a corresponding efficacy for each of the plurality of insomnia therapies, determining an actual insomnia severity that is based at least in part upon a number of insomnia symptoms in the patient, determining an efficacy of the insomnia therapy based at least in part upon the predicted insomnia severity and the actual insomnia severity, and updating the insomnia therapy map to reflect the efficacy.
- These and other objects, features, and characteristics of the present invention, as well as the methods of operation and functions of the related elements of structure and the combination of parts and economies of manufacture, will become more apparent upon consideration of the following description and the appended claims with reference to the accompanying drawings, all of which form a part of this specification, wherein like reference numerals designate corresponding parts in the various figures. It is to be expressly understood, however, that the drawings are for the purpose of illustration and description only and are not intended as a definition of the limits of the invention.
-
FIG. 1 is a depiction of an improved system in accordance with an aspect of the disclosed and claimed concept; -
FIG. 2 is a depiction of a training phase for building an insomnia severity prediction model of the system ofFIG. 1 ; -
FIG. 3 is a depiction of a training phase for building an insomnia therapy map of the system ofFIG. 1 ; -
FIG. 4 is a depiction of the system ofFIG. 1 in a deployment phase; -
FIG. 5 is a further depiction of the system ofFIG. 4 ; and -
FIG. 6 is a flow chart depicting certain aspects of an improved method in accordance with the disclosed and claimed concept. - As used herein, the singular form of “a”, “an”, and “the” include plural references unless the context clearly dictates otherwise. As used herein, the statement that two or more parts or components are “coupled” shall mean that the parts are joined or operate together either directly or indirectly, i.e., through one or more intermediate parts or components, so long as a link occurs. As used herein, “directly coupled” means that two elements are directly in contact with each other. As used herein, “fixedly coupled” or “fixed” means that two components are coupled so as to move as one while maintaining a constant orientation relative to each other.
- As used herein, the word “unitary” means a component is created as a single piece or unit. That is, a component that includes pieces that are created separately and then coupled together as a unit is not a “unitary” component or body. As employed herein, the statement that two or more parts or components “engage” one another shall mean that the parts exert a force against one another either directly or through one or more intermediate parts or components. As employed herein, the term “number” shall mean one or an integer greater than one (i.e., a plurality).
- Directional phrases used herein, such as, for example and without limitation, top, bottom, left, right, upper, lower, front, back, and derivatives thereof, relate to the orientation of the elements shown in the drawings and are not limiting upon the claims unless expressly recited therein.
- The disclosed and claimed
system 4 and method advantageously collects personal profile data (e.g. EHR (chronic condition(s), medication(s)) and monitors various metrics including but not limited to sleep metrics (e.g. WASO, SOL, SE, TST, number of awakenings, sleep stages), activity metrics (e.g. step count, duration, distance, intensity, timing), alertness metrics (e.g. PERCLOS, nap frequency, nap duration), stressors (e.g. Heart Rate (HR), blood pressure, skin conductance, environment temperature), behaviors (e.g. sleep hygiene, caffeine intake frequency and timing), etc. The proposed system monitors these metrics through multi-modality sensors such as under mattress sensors, wearable sensors, etc. In some embodiment, the disclosed and claimed concept includes subjective responses by a patient to a digital survey (e.g. medication side effects). - Insomnia Severity Estimation and Type Trending from Insomnia Symptoms:
- In the disclosed and claimed concept, a patient's insomnia severity is defined by a set of predetermined levels. In the disclosed exemplary embodiment, the predetermined levels are four in quantity (e.g. none, mild, moderate, and severe) based on validated Insomnia Severity Index (ISI). Instead of the determination of an ISI depending on a user's subjective responses to a number of survey questions, the disclosed and claimed concept advantageously uses multiple sensors, such as may include one or more of a photoplethysmogram (PPG), a step counter, a Global Positioning System (GPS) sensor, a HR sensor, a Galvanic Skin Response (GSR) sensor, a room temperature sensor) to obtain a number of objective insomnia-related physiological measures, such as, SOL, WASO, SE, TST, activity timing, duration, and intensity, and alertness, and further develops a formula to integrate all the various metrics into an insomnia severity score (e.g. maximum is 100) and map to a predefined insomnia severity level. The formula can be any type of polynomial or other formula that can combine the various metrics and weight them according to various criteria, etc. In some embodiments, this mapping can be shown as in the following Table 1:
-
TABLE 1 Mapping between insomnia severity score and insomnia severity level Insomnia Severity Score (0-100) Insomnia Level (4 levels) 0-24 none 25-49 mild 50-74 moderate 75-100 severe - This method can be used for evaluating the actual insomnia severity level while an insomnia therapy (or no therapy) is applied to an individual patient. In addition, this module advantageously trends an insomnia type over a predefined moving time window (e.g. weekly) to inform the therapy recommendation.
- Insomnia Severity Prediction from Behaviors, Biometrics, and Stressors (Personal/Environmental):
- To build an insomnia severity prediction model 8 of the
system 4, the present invention captures the indications/data that are relevant insomnia severity. These indications/data include one or more of sleep metrics (last night), sleep debt, stress level, caffeine intake amount and timing, late and hard exercises, hot or cold room temperature, etc. and are collected through a sleepmetrics sensing module 74, a relatedbehaviors sensing module 90, an activitymetrics sensing module 78, a personalstressor sensing module 83, an environmentalstressor sensing module 84, and a personal profile 92 (e.g. chronic conditions and other conditions). In addition, thesystem 4 collects insomnia metrics such as sleep metrics (tonight) via a sleepmetrics sensing module 72 and alertness metrics (tomorrow) via analertness sensing module 76 to evaluate the insomnia severity via an insomniametrics evaluation module 40 that can be said to include the sleepmetrics sensing module 72 and thealertness sensing module 76. Based on the collected data sets (insomnia severity, relevant metrics/data), the disclosed and claimed concept advantageously builds a machine learning model in a training phase as illustrated inFIG. 2 . In a deployment phase as shown inFIG. 4 , this model is used as an insomnia severity prediction model 8 to predict an actual insomnia severity level (e.g. tonight) based on one or more of the relevant behaviors, biometrics, and personal/environmental stressors (e.g. past 24 hours), and projected bedtime, by way of example. - To enable the
system 4 to output a personalized insomnia therapy recommendation, the disclosed and claimed concept advantageously creates a personalized insomnia therapy map that tracks insomnia severity and insomnia type based on the history of therapy efficacy in the individual patient. - The disclosed and claimed concept advantageously begins with a default insomnia therapy map that is not yet personalized but that is instead based initially upon population data such as can be derived from clinical guidelines, clinical study results, review articles, etc. As an individual patient uses an insomnia therapy, which is defined herein as being either a single insomnia therapy or multiple therapies combined, the proposed system tracks the specific therapy the actual insomnia severity, and the insomnia type and also evaluates the resultant therapy efficacy so that a personalized insomnia severity and type therapy map can be built based on history of the personalized therapy efficacy.
- As CBTI is the core therapy for insomnia and it contains multiple aspects such as, sleep hygiene education, sleep restriction therapy, etc., CBTI therapy contains many possible methods. In addition, CBTI alone might not be enough, and additional pharmacological therapy might be required for an individual. However, some medications are specific to certain type of insomnia. The disclosed and claimed concept thus advantageously also trends the insomnia type of an individual patient over the predefined period of time to inform the proper choice of the medication, if needed. Hence, the disclosed and claimed concept advantageously also includes the insomnia type along with the insomnia severity in the insomnia therapy map.
- Furthermore, the disclosed and claimed concept advantageously saves up to a predefined quantity of therapies (up to three, by way of example) for each combination of insomnia severity level and insomnia type so that a plurality of personalized alternative and optional insomnia therapies can be recommended as well. To support the recommendation, the exemplary insomnia therapy map illustrated in Table 2 below is organized as a ranked list for each severity level based on the statistics of efficacy history of an individual.
-
TABLE 2 Personalized Insomnia Severity and Insomnia Type Therapy Map Insomnia Insomnia type Therapy IDs Severity (Onset--O/ (ID with max Past Efficacies Level Maintenance--M) efficacy-bolded) (Max-bolded) moderate O [3, 17, 25] [80, 68, 74] moderate O & M [4, 11, 39] [55, 77, 69] moderate M [9, 33, 2] [67, 69, 70] severe M [7, 19, 41] [75, 66, 70] severe O & M [31, 8, 53] [65, 68, 60] severe O [6, 22, 40] [60, 50, 58] mild O & M [45, 12, 18] [82, 90, 87] mild M [23, 37, 5] [80, 78, 84] mild O [10, 26,35] [77, 63, 71] - In the disclosed and claimed concept, each therapy ID in Table 2 can be one or more specific therapy methods. For instance, Therapy ID 1 represents CBTI 1 (e.g. “choose a relaxing activity for half an hour before bedtime”) as illustrated in Table 3 below. By way of further example, Therapy ID 7 represents a combination of CBTI 1 and Med N (e.g. eszopiclone). In some embodiments, as an individual patient continuously uses the proposed system, this table becomes enhanced and personalized.
-
TABLE 3 Relationship of Therapy Identification and Associated Therapy Choices Therapy Med N ID CBTI 1 . . . CBTI K Med 1 . . . (e.g. 15) 1 X 2 X 3 X 4 X X 5 X X X 6 X X 7 X X . . . X M (e.g. 35) X X - To build a personalized insomnia severity and insomnia type therapy ranked map informed by therapy efficacy, the disclosed and claimed concept advantageously creates a therapy efficacy evaluation module or method to evaluate therapy efficacy. The disclosed and claimed concept advantageously evaluates the therapy efficacy through the following processes.
- Sleep quality score: The disclosed and claimed concept advantageously determines a sleep quality score by using various sleep metrics (e.g., using one or more of SE, WASO, number of awakenings, SOL, deep sleep percentage, TST, etc.). The disclosed and claimed concept advantageously monitors the sleep metrics of a patient during the night while a specific therapy is in use. The maximum sleep quality score representing the best sleep quality is defined as 100.
- Alertness score: The disclosed and claimed concept advantageously determines a next-day alertness score by using various metrics (e.g. PERCLOS, number of naps, and duration of naps). The disclosed and claimed concept advantageously monitors these metrics during the day after applying a therapy and evaluates the alertness score. The maximum alertness score corresponding to the maximum alertness is defined as 100.
- Reduction score of insomnia severity: The disclosed and claimed concept advantageously compares the predicted insomnia severity (i.e. before going to the bed) from the insomnia severity prediction model 8 with the actual insomnia severity informed by the aforementioned sleep quality score and alertness score via an insomnia metrics evaluation module 24 (i.e. measured during the night while a specific therapy is in use) to estimate the reduction score. In some embodiments, the insomnia metrics evaluation module combines the results from the sleep quality score and the alertness score into a composite score (i.e. insomnia severity score) that corresponds to a predefined severity level. In some embodiments, the reduction score is determined via a percentage reduction by using a ratio (e.g. actual insomnia severity score/predicted insomnia severity score). In some embodiments, the reduction score is evaluated by the difference between the predicted insomnia severity score and the actual severity score. The maximum reduction score is defined as 100 which represents the maximum efficacy.
- The disclosed and claimed concept advantageously evaluates the therapy efficacy for each therapy used by a patient and saves the therapy efficacy along with the insomnia severity and the insomnia type and the specific therapy in the personalized insomnia therapy map so that the insomnia therapy map reflect the ongoing therapy efficacy in the patient of the various insomnia therapies that have been employed. A building phase for building the insomnia therapy map is illustrated in
FIG. 3 . This insomnia therapy map evolves as the patient continues to use the system. - As in shown in
FIG. 3 , to create aninsomnia therapy map 44, thesystem 4 advantageously creates a default therapy list (e.g. single therapy or combined therapy) with a number of insomnia severities and a number of insomnia types along with a number of potential therapy efficacies that may be based upon population data or otherwise. The disclosed and claimed system advantageously uses this default list to initially provide an insomnia therapy recommendation. As the patient continues to use thesystem 4, the personalizedinsomnia therapy map 44 that lists insomnia severity and insomnia type and that is ranked by corresponding therapy efficacy is built, and thesystem 4 uses theinsomnia therapy map 44 to provides a personalized recommendation to achieve optimized therapy efficacy and to improve sleep quality of the patient as illustrated inFIG. 4 . - The
system 4 includes atherapy recommendation module 48 that prioritizes therapy swapping in order to avoid desensitization, habituation, or potential side effects from chronic usage of a given therapy regimen. In one example, prescription hypnotics are not recommended for any more than, for instance, seven days per month. In another example, diphenhydramine and doxylamine succinate (OTC sedating antihistamines) quickly build a tolerance effect and are not recommended any more than, for instance, four days per month. In alternative embodiments, the tolerance effect for each sleep intervention is tracked independently and, when a suspected tolerance is detected as having begun to be built, as detected as a reduced efficacy of the therapeutic intervention, as tracked and trended by a therapyefficacy evaluation module 52 of the system, the intervention is not recommended for a specific “abstinence period” (e.g. two weeks). - In some embodiments, “no intervention required” is suggested for nights when predicted insomnia severity is low. Alternatively, typical sleep hygiene advice can be given on nights when predicted insomnia severity is low (e.g. messaging such as, “You've had a great day today and it'll soon be time to be ready for a great night. Remember to take time to wind down before bed tonight. A nice, calming activity before bed helps prepare the mind and body for rest.”). In alternative embodiments, a placebo treatment may be recommended on nights with low to moderate insomnia severity (e.g. lavender, etc.).
- The
apparatus 4 is depicted inFIGS. 4 and 5 .Apparatus 4 can be employed in performing animproved method 100 that is likewise in accordance with the disclosed and claimed concept and at least a portion of which is depicted in a schematic fashion inFIG. 6 .Apparatus 4 can be characterized as including aprocessor apparatus 56 that can be said to include aprocessor 60 and astorage 64 that are connected with one another.Storage 64 is in the form of a non-transitory storage medium that has stored therein a number ofroutines 68 that are likewise in the form of a non-transitory storage medium and that include instructions which, when executed onprocessor 60,cause apparatus 4 to perform certain operations such as are mentioned elsewhere herein. - In addition to the other components of
system 4 noted hereinbefore,system 4 includes the sleepmetrics sensing module 72 comprising a photoplethysmogram (PPG) 74, thealertness sensing module 76, the activitymetrics sensing module 78 comprising at least one of astep counter 80 and a Global Positioning System (GPS)sensor 82, the personalstressor sensing module 83 comprising a Galvanic Skin Response (GSR)sensor 86, the environmentalstressor sensing module 84 comprising aroom temperature sensor 88, the relatedbehaviors sensing module 90, and thepersonal profile 92 of the patient. These can all be considered to be a part of aninput apparatus 94 ofsystem 4 that provides input signals toprocessor 60.System 4 further includes anoutput apparatus 96 that receives output signals fromprocessor 60 and that provides outputs that are detectable by the patient, such as audible outputs, visual outputs, and the like without limitation. - Certain aspects of the
improved method 100 noted hereinbefore are depicted in the flow chart shown generally inFIG. 6 . For each of a plurality of periods of attempted sleep by the patient, themethod 100 performs the operations depicted generally inFIG. 6 . For instance, themethod 100 includes determining, as at 105, a predicted insomnia severity based upon inputs from the insomnia severity prediction model 8. Themethod 100 also includes outputting, as at 110, a recommendation of an insomnia therapy based upon the predicted insomnia severity and input from theinsomnia therapy map 44. Themethod 100 also includes determining, as at 115, an actual insomnia severity that is based upon a number of insomnia symptoms in the patient. The various insomnia symptoms can be obtained viainput apparatus 94. Themethod 100 further includes determining, as at 120, an efficacy of the insomnia therapy based upon the predicted insomnia severity and the actual insomnia severity. Themethod 100 also includes, as at 125, updating theinsomnia therapy map 44 to reflect the efficacy. Such operations are repeated, as noted hereinbefore, for each of a plurality of periods of attempted sleep by the patient. Over time, therefore, theinsomnia therapy map 44 is gradually personalized to the patient in order to provide improved recommendations of insomnia therapies, which is desirable for the patient. Other benefits will be apparent. - In the claims, any reference signs placed between parentheses shall not be construed as limiting the claim. The word “comprising” or “including” does not exclude the presence of elements or steps other than those listed in a claim. In a device claim enumerating several means, several of these means may be embodied by one and the same item of hardware. The word “a” or “an” preceding an element does not exclude the presence of a plurality of such elements. In any device claim enumerating several means, several of these means may be embodied by one and the same item of hardware. The mere fact that certain elements are recited in mutually different dependent claims does not indicate that these elements cannot be used in combination.
- Although the invention has been described in detail for the purpose of illustration based on what is currently considered to be the most practical and preferred embodiments, it is to be understood that such detail is solely for that purpose and that the invention is not limited to the disclosed embodiments, but, on the contrary, is intended to cover modifications and equivalent arrangements that are within the spirit and scope of the appended claims. For example, it is to be understood that the present invention contemplates that, to the extent possible, one or more features of any embodiment can be combined with one or more features of any other embodiment.
Claims (20)
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/363,714 US20220020461A1 (en) | 2020-07-20 | 2021-06-30 | Contextualized personalized insomnia therapy regimen, system, and method |
JP2023503459A JP2023537223A (en) | 2020-07-20 | 2021-07-16 | Contextualized and personalized insomnia treatment regimens, systems and methods |
EP21751773.9A EP4182951A1 (en) | 2020-07-20 | 2021-07-16 | Contextualized personalized insomnia therapy regimen, system, and method |
PCT/EP2021/070052 WO2022017991A1 (en) | 2020-07-20 | 2021-07-16 | Contextualized personalized insomnia therapy regimen, system, and method |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063054197P | 2020-07-20 | 2020-07-20 | |
US17/363,714 US20220020461A1 (en) | 2020-07-20 | 2021-06-30 | Contextualized personalized insomnia therapy regimen, system, and method |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220020461A1 true US20220020461A1 (en) | 2022-01-20 |
Family
ID=77265057
Family Applications (8)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/106,827 Active 2042-02-03 US11837106B2 (en) | 2020-07-20 | 2020-11-30 | System and method to monitor and titrate treatment for high altitude-induced central sleep apnea (CSA) |
US17/132,424 Pending US20220020286A1 (en) | 2020-07-20 | 2020-12-23 | Optimized effectiveness based sleep aid management |
US17/132,503 Pending US20220020492A1 (en) | 2020-07-20 | 2020-12-23 | Predicting orthosomnia in an individual |
US17/138,242 Pending US20220016369A1 (en) | 2020-07-20 | 2020-12-30 | System and method for determining and providing personalized pap therapy recommendations for a patient |
US17/138,272 Pending US20220016371A1 (en) | 2020-07-20 | 2020-12-30 | System and method for osa prevention and pap therapy weaning |
US17/363,714 Pending US20220020461A1 (en) | 2020-07-20 | 2021-06-30 | Contextualized personalized insomnia therapy regimen, system, and method |
US17/363,353 Pending US20220020468A1 (en) | 2020-07-20 | 2021-06-30 | Method and system to optimize therapy efficacy |
US17/363,242 Pending US20220020463A1 (en) | 2020-07-20 | 2021-06-30 | Method and system to optimize pharmacotherapy |
Family Applications Before (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/106,827 Active 2042-02-03 US11837106B2 (en) | 2020-07-20 | 2020-11-30 | System and method to monitor and titrate treatment for high altitude-induced central sleep apnea (CSA) |
US17/132,424 Pending US20220020286A1 (en) | 2020-07-20 | 2020-12-23 | Optimized effectiveness based sleep aid management |
US17/132,503 Pending US20220020492A1 (en) | 2020-07-20 | 2020-12-23 | Predicting orthosomnia in an individual |
US17/138,242 Pending US20220016369A1 (en) | 2020-07-20 | 2020-12-30 | System and method for determining and providing personalized pap therapy recommendations for a patient |
US17/138,272 Pending US20220016371A1 (en) | 2020-07-20 | 2020-12-30 | System and method for osa prevention and pap therapy weaning |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/363,353 Pending US20220020468A1 (en) | 2020-07-20 | 2021-06-30 | Method and system to optimize therapy efficacy |
US17/363,242 Pending US20220020463A1 (en) | 2020-07-20 | 2021-06-30 | Method and system to optimize pharmacotherapy |
Country Status (5)
Country | Link |
---|---|
US (8) | US11837106B2 (en) |
EP (8) | EP4182948A1 (en) |
JP (2) | JP2023534133A (en) |
CN (5) | CN116171478A (en) |
WO (8) | WO2022017893A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2022328131A1 (en) * | 2021-08-09 | 2024-02-15 | Y-Prime, LLC | Risk assessment and intervention platform architecture for predicting and reducing negative outcomes in clinical trials |
WO2024107108A1 (en) * | 2022-11-14 | 2024-05-23 | National University Of Singapore | Computer implemented methods of generating dose recommendations |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10376670B2 (en) * | 2013-07-08 | 2019-08-13 | Resmed Sensor Technologies Limited | Methods and systems for sleep management |
US11197633B2 (en) * | 2013-10-09 | 2021-12-14 | Resmed Sensor Technologies Limited | Fatigue monitoring and management system |
US11367519B1 (en) * | 2018-07-19 | 2022-06-21 | Great Lakes Neurotechnologies Inc. | Systems and methods for precision or personal pharmaceutical dosing |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6349724B1 (en) * | 2000-07-05 | 2002-02-26 | Compumedics Sleep Pty. Ltd. | Dual-pressure blower for positive air pressure device |
US20050080348A1 (en) | 2003-09-18 | 2005-04-14 | Stahmann Jeffrey E. | Medical event logbook system and method |
US7468040B2 (en) * | 2003-09-18 | 2008-12-23 | Cardiac Pacemakers, Inc. | Methods and systems for implantably monitoring external breathing therapy |
US7680537B2 (en) | 2003-08-18 | 2010-03-16 | Cardiac Pacemakers, Inc. | Therapy triggered by prediction of disordered breathing |
EP1670547B1 (en) * | 2003-08-18 | 2008-11-12 | Cardiac Pacemakers, Inc. | Patient monitoring system |
US7591265B2 (en) * | 2003-09-18 | 2009-09-22 | Cardiac Pacemakers, Inc. | Coordinated use of respiratory and cardiac therapies for sleep disordered breathing |
SE0401208D0 (en) * | 2004-05-10 | 2004-05-10 | Breas Medical Ab | Multilevel fan |
JP5425793B2 (en) * | 2007-10-12 | 2014-02-26 | ペイシェンツライクミー, インコーポレイテッド | Personal management and comparison of medical conditions and outcomes based on patient community profiles |
WO2010080405A1 (en) * | 2008-12-19 | 2010-07-15 | The Board Of Trustees Of The University Of Illinois | Detection and prediction of physiological events in people with sleep disordered breathing using a lamstar neural network |
US8979730B2 (en) * | 2009-06-04 | 2015-03-17 | Koninklijke Philips N.V. | Method and system for providing behavioural therapy for insomnia |
US8684006B2 (en) * | 2010-03-26 | 2014-04-01 | Advanced Brain Monitoring, Inc. | Systems and methods for optimizing oral appliance therapy for the treatment of sleep apnea |
WO2012071354A2 (en) * | 2010-11-23 | 2012-05-31 | Sanitas, Inc. | Disease management system using personalized education, patient support community and telemonitoring |
US20150282768A1 (en) * | 2012-09-29 | 2015-10-08 | Aliphcom | Physiological signal determination of bioimpedance signals |
US11712557B2 (en) * | 2013-05-30 | 2023-08-01 | Neurostim Technologies Llc | Detection and treatment of obstructive sleep apnea |
US20190076031A1 (en) * | 2013-12-12 | 2019-03-14 | Alivecor, Inc. | Continuous monitoring of a user's health with a mobile device |
US11437125B2 (en) * | 2014-06-13 | 2022-09-06 | University Hospitals Cleveland Medical Center | Artificial-intelligence-based facilitation of healthcare delivery |
US9241079B1 (en) * | 2014-06-27 | 2016-01-19 | Sap Se | Mobile application usage monitor |
US10278638B2 (en) * | 2014-07-21 | 2019-05-07 | Withings | System and method to monitor and assist individual's sleep |
US20160106344A1 (en) * | 2014-10-14 | 2016-04-21 | Milad Nazari | Methods and systems for detecting movement disorder |
US9889271B2 (en) * | 2015-01-05 | 2018-02-13 | Inteliclinic Inc. | System, apparatus and method for treating sleep disorder symptoms |
CA3081166A1 (en) * | 2015-01-06 | 2016-07-14 | David Burton | Mobile wearable monitoring systems |
US10690763B2 (en) * | 2015-04-20 | 2020-06-23 | Resmed Sensor Technologies Limited | Detection and identification of a human from characteristic signals |
JP6767394B2 (en) * | 2015-05-29 | 2020-10-14 | コーニンクレッカ フィリップス エヌ ヴェKoninklijke Philips N.V. | Devices to increase patient compliance with treatment for upper respiratory tract disease, how the devices operate, and computer programs |
US10582890B2 (en) * | 2015-08-28 | 2020-03-10 | Awarables Inc. | Visualizing, scoring, recording, and analyzing sleep data and hypnograms |
US10258272B2 (en) * | 2015-10-08 | 2019-04-16 | International Business Machines Corporation | Identifying stress levels associated with context switches |
WO2018129351A1 (en) * | 2017-01-05 | 2018-07-12 | Shriram Raghunathan | Restless leg syndrome or overactive nerve treatment |
US20190000349A1 (en) * | 2017-06-28 | 2019-01-03 | Incyphae Inc. | Diagnosis tailoring of health and disease |
US11363984B2 (en) * | 2017-09-12 | 2022-06-21 | Snooze, Inc. | Method and system for diagnosis and prediction of treatment effectiveness for sleep apnea |
US20190108912A1 (en) * | 2017-10-05 | 2019-04-11 | Iquity, Inc. | Methods for predicting or detecting disease |
IL255255A0 (en) * | 2017-10-25 | 2017-12-31 | Optimata Ltd | System and method for prediction of medical treatment effect |
WO2019084448A1 (en) * | 2017-10-26 | 2019-05-02 | Radial Medical, Inc. | Adaptive compression therapy systems and methods |
US11638795B2 (en) * | 2018-06-29 | 2023-05-02 | Koninklijke Philips N.V. | System and method for providing enhanced PAP metrics |
CA3152384A1 (en) | 2018-09-06 | 2020-03-12 | Ian Cooke | Method of treating a sleep breathing disorder |
US11783949B2 (en) * | 2018-11-30 | 2023-10-10 | Ariel Precision Medicine, Inc. | Methods and systems for severity calculator |
CL2019000057A1 (en) | 2019-01-08 | 2019-04-12 | Sleepmed Spa | Method and system for predicting risk index in conditions of chronic intermittent hypobaric hypoxia by recording physiological parameters and anthropometric variables in real time. |
CN114072827A (en) * | 2019-03-15 | 2022-02-18 | 3M创新有限公司 | Personalized medicine using causal models |
AU2020264769A1 (en) * | 2019-05-02 | 2021-12-23 | Closed Loop Medicine Ltd | Methods and systems for providing personalised medicine to a patient |
US20210007659A1 (en) * | 2019-06-28 | 2021-01-14 | Teleplus Healthcare LLC | System and method for sleep disorders: screening, testing and management |
JP2022542580A (en) * | 2019-07-25 | 2022-10-05 | インスパイア・メディカル・システムズ・インコーポレイテッド | Sleep detection for sleep-disordered breathing (SDB) care |
WO2021061655A1 (en) * | 2019-09-24 | 2021-04-01 | Delos Living Llc | Systems and methods for enhancing sleep patterns |
EP4038629A1 (en) * | 2019-09-30 | 2022-08-10 | F. Hoffmann-La Roche AG | Prediction of disease status |
US20220406420A1 (en) * | 2019-09-30 | 2022-12-22 | Resmed Sensor Technologies Limited | Systems and methods for predicting adoption of a therapy |
US20220362221A1 (en) * | 2019-11-04 | 2022-11-17 | Apnimed, Inc. (Delaware) | Combination pharmacological interventions for multiple mechanisms of obstructive sleep apnea |
KR20220149552A (en) * | 2020-03-02 | 2022-11-08 | 슬립 넘버 코포레이션 | Bed with user context sensing feature |
CN113520340B (en) * | 2020-04-15 | 2022-11-08 | 华为技术有限公司 | Sleep report generation method, device, terminal and storage medium |
WO2021220247A1 (en) * | 2020-04-30 | 2021-11-04 | Resmed Sensor Technologies Limited | Systems and methods for promoting a sleep stage of a user |
-
2020
- 2020-11-30 US US17/106,827 patent/US11837106B2/en active Active
- 2020-12-23 US US17/132,424 patent/US20220020286A1/en active Pending
- 2020-12-23 US US17/132,503 patent/US20220020492A1/en active Pending
- 2020-12-30 US US17/138,242 patent/US20220016369A1/en active Pending
- 2020-12-30 US US17/138,272 patent/US20220016371A1/en active Pending
-
2021
- 2021-06-30 US US17/363,714 patent/US20220020461A1/en active Pending
- 2021-06-30 US US17/363,353 patent/US20220020468A1/en active Pending
- 2021-06-30 US US17/363,242 patent/US20220020463A1/en active Pending
- 2021-07-15 WO PCT/EP2021/069691 patent/WO2022017893A1/en unknown
- 2021-07-15 EP EP21751506.3A patent/EP4182948A1/en active Pending
- 2021-07-15 WO PCT/EP2021/069677 patent/WO2022017891A1/en unknown
- 2021-07-15 CN CN202180060534.1A patent/CN116171478A/en active Pending
- 2021-07-15 JP JP2022578701A patent/JP2023534133A/en active Pending
- 2021-07-15 EP EP21751507.1A patent/EP4182939A1/en active Pending
- 2021-07-16 WO PCT/EP2021/070048 patent/WO2022017989A1/en unknown
- 2021-07-16 EP EP21751771.3A patent/EP4182950A1/en active Pending
- 2021-07-16 CN CN202180059498.7A patent/CN116210057A/en active Pending
- 2021-07-16 WO PCT/EP2021/070052 patent/WO2022017991A1/en unknown
- 2021-07-16 EP EP21751773.9A patent/EP4182951A1/en active Pending
- 2021-07-16 JP JP2023503459A patent/JP2023537223A/en active Pending
- 2021-07-17 CN CN202180060076.1A patent/CN116171477A/en active Pending
- 2021-07-17 EP EP21751774.7A patent/EP4182952A1/en active Pending
- 2021-07-17 WO PCT/EP2021/070062 patent/WO2022017993A1/en unknown
- 2021-07-17 WO PCT/EP2021/070063 patent/WO2022017994A1/en unknown
- 2021-07-17 EP EP21751995.8A patent/EP4182953A1/en active Pending
- 2021-07-17 CN CN202180060209.5A patent/CN116134548A/en active Pending
- 2021-07-20 WO PCT/EP2021/070192 patent/WO2022018048A1/en unknown
- 2021-07-20 EP EP21754705.8A patent/EP4182954A1/en active Pending
- 2021-07-20 WO PCT/EP2021/070193 patent/WO2022018049A1/en unknown
- 2021-07-20 EP EP21754706.6A patent/EP4182938A1/en active Pending
- 2021-07-20 CN CN202180059048.8A patent/CN116134547A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10376670B2 (en) * | 2013-07-08 | 2019-08-13 | Resmed Sensor Technologies Limited | Methods and systems for sleep management |
US11197633B2 (en) * | 2013-10-09 | 2021-12-14 | Resmed Sensor Technologies Limited | Fatigue monitoring and management system |
US11367519B1 (en) * | 2018-07-19 | 2022-06-21 | Great Lakes Neurotechnologies Inc. | Systems and methods for precision or personal pharmaceutical dosing |
Also Published As
Publication number | Publication date |
---|---|
WO2022017994A1 (en) | 2022-01-27 |
JP2023534133A (en) | 2023-08-08 |
CN116134548A (en) | 2023-05-16 |
WO2022018049A1 (en) | 2022-01-27 |
WO2022018048A1 (en) | 2022-01-27 |
EP4182938A1 (en) | 2023-05-24 |
EP4182939A1 (en) | 2023-05-24 |
WO2022017891A1 (en) | 2022-01-27 |
US20220020501A1 (en) | 2022-01-20 |
WO2022017991A1 (en) | 2022-01-27 |
US20220016371A1 (en) | 2022-01-20 |
CN116171477A (en) | 2023-05-26 |
EP4182952A1 (en) | 2023-05-24 |
US20220020492A1 (en) | 2022-01-20 |
WO2022017993A1 (en) | 2022-01-27 |
EP4182951A1 (en) | 2023-05-24 |
WO2022017989A1 (en) | 2022-01-27 |
CN116171478A (en) | 2023-05-26 |
EP4182953A1 (en) | 2023-05-24 |
WO2022017893A1 (en) | 2022-01-27 |
EP4182948A1 (en) | 2023-05-24 |
EP4182950A1 (en) | 2023-05-24 |
US20220020468A1 (en) | 2022-01-20 |
US11837106B2 (en) | 2023-12-05 |
EP4182954A1 (en) | 2023-05-24 |
CN116134547A (en) | 2023-05-16 |
US20220020286A1 (en) | 2022-01-20 |
US20220020463A1 (en) | 2022-01-20 |
US20220016369A1 (en) | 2022-01-20 |
CN116210057A (en) | 2023-06-02 |
JP2023537223A (en) | 2023-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6440808B2 (en) | Personal management and monitoring of medical conditions | |
Tyson et al. | The relationship between balance, disability, and recovery after stroke: predictive validity of the Brunel Balance Assessment | |
Vickers et al. | Perceptual indices of performance: the measurement of ‘inspection time’and ‘noise’in the visual system | |
Patel et al. | Patient-centered design criteria for wearable seizure detection devices | |
Thun et al. | An actigraphic validation study of seven morningness-eveningness inventories | |
US20220020461A1 (en) | Contextualized personalized insomnia therapy regimen, system, and method | |
CN116195002A (en) | Sleep disturbance prediction system and method based on sleep reaction monitoring | |
Wilkinson et al. | Monitoring health status in long term care through the use of ambient technologies and serious games | |
JP5046364B2 (en) | Sleep condition evaluation system and program thereof | |
JP2023547875A (en) | Personalized cognitive intervention systems and methods | |
CN113383395A (en) | Decision support software system for sleep disorder recognition | |
JP6534601B2 (en) | Life rhythm recommendation device | |
US20210358628A1 (en) | Digital companion for healthcare | |
Pace-Schott et al. | Failure to find executive function deficits following one night's total sleep deprivation in university students under naturalistic conditions | |
Katz-Leurer et al. | Effect of concurrent cognitive tasks on gait features among children post-severe traumatic brain injury and typically-developed controls | |
de Vries et al. | Moderation of the stressor-strain process in interns by heart rate variability measured with a wearable and smartphone app: Within-subject design using continuous monitoring | |
Wilson et al. | Exploring the relationship between sleep and expertise in endurance sport athletes | |
US20240156398A1 (en) | System and method for improving sleep quality | |
Katz-Leurer et al. | Pediatric cardio-autonomic response to variable effort after severe traumatic brain injury | |
Gomez et al. | The role of ethnicity and environment in the regulation of response to sensory stimulus in children: protocol and pilot findings of a neurophysiological study | |
Lim et al. | Developing a mobile wellness management system for healthy lifestyle by analyzing daily living activities | |
Daurat et al. | Memory monitoring and memory control in patients suffering from obstructive sleep apnoea syndrome | |
JP2022040945A (en) | Method for determining stress tolerance | |
EP3957244A1 (en) | Method for detection of a relapse into a depression or mania state based on activity data and/or data obtained by questioning the patient | |
Diehl et al. | Exercise partner preferences, social physique anxiety, and social discomfort in exercise settings among women university wellness center patrons |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: KONINKLIJKE PHILIPS N.V., NETHERLANDS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SHELLY, BENJAMIN IRWIN;CHEN, XIA;VON HOLLEN, DIRK ERNEST;SIGNING DATES FROM 20220415 TO 20220418;REEL/FRAME:059633/0088 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |